Evidence map›Paper›PMID 40244424›Full record

ArticleCancer immunology, immunotherapy : CII2025

Durable response to nivolumab in combination with regional hyperthermia in a patient with PD-L1-negative metastatic head and neck squamous cell carcinoma.

Luc M Berclaz, Anton Burkhard-Meier, Axel Lechner, Michael Völkl, Sinan E Güler, Sultan Abdel-Rahman, Sina Mansoorian, Wolfgang G Kunz, Thomas Knösel, Martin Canis and 4 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Luc M BerclazDepartment of Internal Medicine III, University Hospital, LMU Munich, Munich, Germany. luc.berclaz@med.uni-muenchen.de.
Anton Burkhard-MeierDepartment of Internal Medicine III, University Hospital, LMU Munich, Munich, Germany.
Axel LechnerDeparment of Otorhinolaryngology, University Hospital, LMU Munich, Munich, Germany.
Michael VölklDepartment of Internal Medicine III, University Hospital, LMU Munich, Munich, Germany.
Sinan E GülerDepartment of Internal Medicine III, University Hospital, LMU Munich, Munich, Germany.
Sultan Abdel-RahmanDepartment of Internal Medicine III, University Hospital, LMU Munich, Munich, Germany.
Sina MansoorianDepartment of Radiation Oncology, University Hospital, LMU Munich, Munich, Germany.
Wolfgang G KunzDepartment of Radiology, University Hospital, LMU Munich, Munich, Germany.
Thomas KnöselInstitute of Pathology, LMU Munich, Munich, Germany.
Martin CanisDeparment of Otorhinolaryngology, University Hospital, LMU Munich, Munich, Germany.
Michael von Bergwelt-BaildonDepartment of Internal Medicine III, University Hospital, LMU Munich, Munich, Germany.
Rolf D IsselsDepartment of Internal Medicine III, University Hospital, LMU Munich, Munich, Germany.
Dorit Di GioiaDepartment of Internal Medicine III, University Hospital, LMU Munich, Munich, Germany.
Lars H LindnerDepartment of Internal Medicine III, University Hospital, LMU Munich, Munich, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We report a long-lasting response to the immune checkpoint inhibitor nivolumab in combination with regional hyperthermia (RHT) in a patient with recurrent metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) and negative programmed death ligand 1 (PD-L1) expression. Treatment was well tolerated with no local side effects. Tumor-related symptoms in the orbital and masticator area gradually decreased under treatment with nivolumab and RHT. Over the course of treatment, magnetic resonance imaging (MRI) showed a local tumor control in the heated tumor areas, while metastatic lesions developed in areas outside of the RHT field. This is the first case report demonstrating the feasibility and clinical potential of the addition of RHT in this patient collective with poor outcomes and low response rates to immune checkpoint inhibitors. RHT might be an additional tool to activate an immunogenic milieu responsive to immune checkpoint inhibitors.

Indexed as

Antineoplastic Agents, ImmunologicalB7-H1 AntigenHead and Neck NeoplasmsHyperthermia, InducedImmune Checkpoint InhibitorsNivolumabSquamous Cell Carcinoma of Head and NeckCombined Modality TherapyHumansMaleMiddle AgedAntineoplastic Agents, ImmunologicalB7-H1 AntigenCD274 protein, humanImmune Checkpoint InhibitorsNivolumabHead and neck cancerImmune checkpoint inhibitorsImmunotherapyRegional hyperthermia

Identifiers

PMID40244424
PMCPMC12006646

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.